CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-06-02): New biomarkers may predict liver tumor aggressiveness

Science

New biomarkers may predict liver tumor aggressiveness

Last Updated: 2004-06-02 13:30:54 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Expression of vascular endothelial growth factor (VEGF) and the tumor-suppressing gene Rb2/p130 may serve as prognostic markers of the aggressiveness of hepatocellular carcinoma (HCC), according to a report in the May 15th issue of Clinical Cancer Research.

A number of molecular factors have already been shown to be associated with HCC invasiveness, the authors explain, but the identification of other markers is important for predicting patient outcomes and tailoring treatment.

Dr. Pier Paolo Claudio from Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, and colleagues examined the expression of p27, PCNA, tumor-suppressor protein Rb2/p130, and VEGF in 21 cases of HCC to determine their usefulness as prognostic indicators for HCC.

Lack of pRb2/p130 expression and higher VEGF expression were associated with a trend to poor survival, the authors report, and their levels were significantly negatively correlated.

Levels of pRb2/p130 decreased as tumor malignancy increased and tumor cells became less differentiated, the report indicates, whereas VEGF was undetectable in low-grade HCC tumors but increased in advanced tumor malignancy.

Like VEGF, PCNA expression was high in poorly differentiated HCC specimens and progressively decreased in moderately and well-differentiated HCC specimens, the researchers note.

"The majority of the tumors were p27-negative regardless of grade and patient survival," Dr. Claudio told Reuters Health. "In this case, other biological markers are necessary to serve as prognostic indicators."

"The inverse relationship between pRb2/p130 and VEGF can serve as a prognostic indicator to predict which tumors will acquire the necessary genetic modifications to become biologically aggressive even at an early grade," Dr. Claudio said. "This may serve as a valuable tool to direct management decisions early in the course of therapy."

"It is possible that the inverse relationship between the two biomarkers pRb2/p130 and VEGF may exist in other cancer types as well," Dr. Claudio added. "Therefore, it would be necessary to further investigate these proteins in other cancer types."

Clin Cancer Res 2004;10:3509-3517.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.